139 related articles for article (PubMed ID: 36241148)
1. Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation.
Essmann S; Heestermans M; Dadkhah A; Janson D; Wolschke C; Ayuk F; Kröger NM; Langebrake C
Transplant Cell Ther; 2023 Jan; 29(1):42.e1-42.e6. PubMed ID: 36241148
[TBL] [Abstract][Full Text] [Related]
2. Iron Chelation With Deferasirox Increases Busulfan AUC During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation.
Essmann S; Dadkhah A; Janson D; Wolschke C; Ayuk F; Kröger NM; Langebrake C
Transplant Cell Ther; 2022 Feb; 28(2):115.e1-115.e5. PubMed ID: 34775147
[TBL] [Abstract][Full Text] [Related]
3. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation.
Naoum FA; Espósito BP; Ruiz LP; Ruiz MA; Tanaka PY; Sobreira JT; Cançado RD; de Barros JC
Acta Haematol; 2014; 131(4):222-6. PubMed ID: 24335268
[TBL] [Abstract][Full Text] [Related]
4. Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Pan T; Ji Y; Liu H; Tang B; Song K; Wan X; Yao W; Sun G; Wang J; Sun Z
Transplant Cell Ther; 2023 Aug; 29(8):507.e1-507.e8. PubMed ID: 37116582
[TBL] [Abstract][Full Text] [Related]
5. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
[TBL] [Abstract][Full Text] [Related]
6. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study.
Kupesiz FT; Sivrice C; Akinel A; Kintrup GT; Guler E; Kupesiz A
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e26-e34. PubMed ID: 34986131
[TBL] [Abstract][Full Text] [Related]
8. Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.
Atilla E; Toprak SK; Demirer T
Turk J Haematol; 2017 Mar; 34(1):1-9. PubMed ID: 27956374
[TBL] [Abstract][Full Text] [Related]
9. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E
Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
[TBL] [Abstract][Full Text] [Related]
10. Labile plasma iron as an indicator of patient adherence to iron chelation treatment.
Steinberg-Shemer O; Yacobovich J; Cohen M; Cabantchik IZ; Tamary H
Blood Cells Mol Dis; 2018 Jul; 71():1-4. PubMed ID: 29395830
[TBL] [Abstract][Full Text] [Related]
11. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB; Lin KH; Beris P; Forni GL; Taher A; Habr D; Domokos G; Roubert B; Thein SL;
Eur J Haematol; 2011 Oct; 87(4):338-48. PubMed ID: 21649735
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.
Jaekel N; Lieder K; Albrecht S; Leismann O; Hubert K; Bug G; Kröger N; Platzbecker U; Stadler M; de Haas K; Altamura S; Muckenthaler MU; Niederwieser D; Al-Ali HK
Bone Marrow Transplant; 2016 Jan; 51(1):89-95. PubMed ID: 26367238
[TBL] [Abstract][Full Text] [Related]
13. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
Yesilipek MA; Karasu G; Kaya Z; Kuskonmaz BB; Uygun V; Dag I; Ozudogru O; Ertem M
Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.
Chueh HW; Sung KW; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
Pediatr Blood Cancer; 2012 Mar; 58(3):441-7. PubMed ID: 21638755
[TBL] [Abstract][Full Text] [Related]
16. Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Zargari A; Wu S; Greenway A; Cheng K; Kaplan Z
Vox Sang; 2022 May; 117(5):733-737. PubMed ID: 35014065
[TBL] [Abstract][Full Text] [Related]
17. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
[TBL] [Abstract][Full Text] [Related]
18. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.
Cho BS; Jeon YW; Hahn AR; Lee TH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Min WS; Kim HJ
Cancer Med; 2019 Feb; 8(2):501-514. PubMed ID: 30677244
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
20. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Angelucci E; Pilo F
Ann N Y Acad Sci; 2016 Mar; 1368(1):115-21. PubMed ID: 26999450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
